| DB ID | MyCo_1710 |
| Title | Pentraxin-3 as a novel prognostic biomarker in non-neutropenic invasive pulmonary aspergillosis patients |
| Year | 2025 |
| PMID | 39878524 |
| Fungal Diseases involved | Invasive pulmonary aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | The study was approved by the Ethics Committee of all participating hospitals. Informed consent was obtained from all subjects. |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Plasma |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | PTX3 (7.11 ng/mL) |
| Biomarker Full Name | Pentraxin-3 (7.11 ng/mL) |
| Biomarker Type | Prognostic |
| Biomolecule | Protein |
| Geographical Location | China |
| Cohort | Here conducted a prospective, multicenter study from August 2020 to February 2024, enrolling 565 patients with suspected IPA. |
| Cohort No. | 565 |
| Age Group | None |
| P Value | None |
| Sensitivity | 0.734 |
| Specificity | 0.828 |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive pulmonary aspergillosis (IPA) is a fungal infection caused by Aspergillus, typically affecting individuals with immune dysfunction. From 2010 to 2023, there has been a notable increase in the global incidence of invasive aspergillosis, with an estimated 2.113 million new cases each year. This rise is largely attributed to the increasing prevalence of chronic obstructive pulmonary disease (COPD), diabetes, critical illness, and lung cancer. Despite advancements in antifungal therapies, the annual mortality remains high at 85.2%. The high mortality is largely attributed to delayed diagnosis and treatment, as well as the absence of effective risk assessment tools necessary for clinical decision-making. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | PTX3 ELISA kit (DPTX30, Quantikine Human Pentraxin 3 Immunoassay, R&D, USA) |
| Assay Data | None |
| Validation Techniques used | ELISA |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
